Rayner announces launch of RayOne Galaxy spiral IOL

News
Article

The IOL, designed with artificial intelligence, will launch at this year's ESCRS Congress in Barcelona, Spain

The RayOne Galaxy spiral IOL in a package. Image courtesy of Rayner.

Clinical investigators are expected to present their findings on the RayOne Galaxy at this year's ESCRS meeting in Barcelona, Spain. Image courtesy of Rayner.

On Monday, ophthalmic surgery manufacturer Rayner announced a new addition to its intraocular lens (IOL) offering, designed using a proprietary artificial intelligence (AI) engine. In a press release, Rayner, based in Worthing, UK, shared details about the RayOne Galaxy and Galaxy Toric, which will launch at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) Congress in Barcelona, Spain.1 The lens will come fully preloaded across the RayOne product line’s power range and will be immediately available in toric powers.

According to Rayner, the RayOne Galaxy has a unique spiral lens, formulated to deliver a continuous full range of vision and minimise dysphotopsia. The company developed the RayOne Galaxy in conjunction with João Marcelo Lyra, MD, PHD, who is affiliated with Universidade Estadual de Ciências da Saúde de Alagoas (UNCISAL), Maceio, Alagoas, Brazil. Additionally, the IOL was developed using an AI “trained on patient outcomes,” resulting in a non-diffractive optic with 0% light loss. The press release from Rayner noted the lens is the “world’s first spiral IOL designed with artificial intelligence.”

Clinical investigations with RayOne Galaxy began earlier in 2024 in Brazil and throughout Europe.1 Eight leading surgeons began using the RayOne Galaxy in their clinical practices, and a number of those surgeons will present initial findings at a Rayner symposium during the ESCRS Congress. Mr Allon Barsam, Consultant Ophthalmic Surgeon and Director at OCL Vision in London, United Kingdom, said the first patients received the RayOne Galaxy lens at OCL Vision in July. “Their feedback so far has been overwhelmingly positive, with patients reading without glasses and thrilled with their quality of vision,” Mr Barsam reported in the press release.

Tim Clover, CEO of Rayner, gave a statement about the AI-supported development of the lens. “We all read about the life changing potential of AI, but this is a real-world example of technology impacting the outcomes of patients,” he said. “RayOne Galaxy represents a next generation technology in intraocular lenses to enable patients to see without spectacles.”

Reference

1. Rayner announces launch of world’s first spiral IOL designed with AI. Press release. Rayner Group. Published 26 August, 2024.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.